Amylyx Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $3.04B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.39 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.37 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | – | $-0.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-0.37 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.46 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.42 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | -$665.00K | $-0.55 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-1.07 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Press releases
Announcements Amylyx Pharmaceuticals filed with the SEC
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
therapies for diseases with high unmet needs, with a focus on serious and fatal neurodegenerative diseases and endocrine conditions. Maggie, a mom and advocate living with post-bariatric hypoglycemia (PBH). Pancreatic islet cells
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO ® /ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Conference Call July 26, 2023
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA for the
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
Other events · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K